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Abstract
There is growing interest in the use of “distributionally-sensitive” forms of economic evaluation that capture both the impact 
of an intervention upon average population health and the distribution of that health amongst the population. This review aims 
to inform the conduct of distributionally sensitive evaluations in the UK by answering three questions: (1) How averse are 
the UK public towards inequalities in lifetime health between socioeconomic groups? (2) Does this aversion difer depending 
upon the type of health under consideration? (3) Are the UK public as averse to inequalities in health between socioeconomic 
groups as they are to inequalities in health between neutrally framed groups? EMBASE, MEDLINE, EconLit, and SSCI were 
searched for stated preference studies relevant to these questions in October 2017. Of the 2155 potentially relevant papers 
identiied, 15 met the predeined hierarchical eligibility criteria. Seven elicited aversion to inequalities in health between 
socioeconomic groups, and eight elicited aversion between neutrally labelled groups. We ind general, although not univer-
sal, evidence for aversion to inequalities in lifetime health between socioeconomic groups, albeit with signiicant variation 
in the strength of that preference across studies. Second, limited evidence regarding the impact of the type of health upon 
aversion. Third, some evidence that the UK public are more averse to inequalities in lifetime health when those inequalities 
are presented in the context of socioeconomic inequality than when presented in isolation.
Keywords Health inequality aversion · Social preferences · Equity weighting · Fair innings · Systematic review
JEL classiication I14 · D04
Introduction
The UK is an unequal society. If you are poor, you can 
expect to live a shorter life than if you were rich [1, 2], you 
can expect to live with lower average health-related qual-
ity of life [3], and you can expect to experience disability 
at a younger age [4]. This “health gap” is substantial [5]. 
In quality-adjusted life-year (QALY) terms, a person living 
in the most deprived quintile areas of English society can 
expect to experience 11.87 QALYs less in their lifetime than 
a person living in the least deprived areas [3].
Recent evidence suggests the UK public are averse to this 
inequality, and would be willing to sacriice a signiicant 
amount of average population lifetime health to achieve a 
more even distribution of it between socioeconomic groups1 
[6–9]—they appear to be “distributionally sensitive”. In 
contrast, economic evaluation in health is typically “distri-
butionally naïve” [10], and operates under the assumption 
that “a QALY is a QALY is a QALY” [11], irrespective of 
who receives it. This apparent discordance has led some to 
question the democratic legitimacy of distributionally naïve 
approaches, and to call for distributionally sensitive forms 
of economic evaluation, such as “distributional cost-efec-
tiveness analysis” [12–14].
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s1019 8-019-01126 -2) contains 
supplementary material, which is available to authorized users.
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If the UK public’s preferences towards inequalities in 
health are to be captured in distributionally sensitive eco-
nomic evaluation, it would be valuable to understand the 
answers to three questions: (1) How averse are the UK pub-
lic towards inequalities in lifetime health between socioeco-
nomic groups? (2) Does the extent of that aversion difer 
depending upon the type of health (e.g. life extension, pain 
relief or mobility improvement) under consideration? (3) 
Are the UK public as averse to inequalities in health between 
socioeconomic groups as they are to inequalities in health 
between neutrally framed groups? This third question mat-
ters, as it is not immediately obvious whether or not it is 
normatively desirable for social health-related resource allo-
cation decisions to be made based on socioeconomic status, 
or whether they should be based on health alone [15]. This 
systematic review focuses on these three questions.
Previous systematic reviews have focused on general 
public preferences regarding diferent broad criteria for pri-
oritisation [16, 17], or preferences regarding diferences in 
the future health of individuals [18–20]. This is the irst sys-
tematic review to focus explicitly on the UK public’s aver-
sion to inequalities in lifetime health between socioeconomic 
groups, although an unsystematic review has recently been 
published [21]. The scope of this review is restricted to the 
preferences of the public in the UK, as the primary objective 
of the study is to inform distributionally sensitive economic 
evaluation in the UK.
Methods
Search strategy
Four databases were searched: Ovid MEDLINE (1946—
27/10/2017), Ovid EMBASE (1974—26/10/2017), Ovid 
EconLit (1886—30/09/2017), and Web of Science’s Social 
Sciences Citation Index (SSCI) (1956—27/10/2017). All 
searches were undertaken on 27/10/2017.
The search strategy was developed in an iterative fashion. 
First, six “pearls” [22] were identiied as starting points, 
to provide the initial list of key words [6, 8, 23–26]. Sec-
ond, the MeSH headings associated with these papers were 
recorded, and a word frequency analysis of the paper titles/
abstracts was undertaken [27]. These were supplemented 
with additional terms based upon the search questions to 
generate an initial search strategy.2 Following this, the ref-
erence lists of the pearls were reviewed, to identify addi-
tional papers. The sensitivity of the draft search strategy 
was then tested in MEDLINE, by assessing whether or not 
it could return the papers identiied from those reference 
lists. If a paper was not identiied, the search strategy was 
then updated with key terms from the unidentiied paper. 
Further scoping searches were then conducted based upon 
this revised strategy, and the reference lists of potentially 
relevant papers scanned for other potentially relevant papers.
The search strategy was then tested again to assess 
whether it identiied all papers identiied in scoping searches, 
reined as needed, and the same process repeated until the 
reference list of all papers identiied in scoping searches 
were picked up by the search strategy. The inal MEDLINE 
search strategy is detailed in Online Appendix 1. Following 
the screening of the database search results, the selected 
papers were reviewed in detail, to identify potentially rel-
evant journal publications, or grey literature, not captured 
within this search. These papers were then treated as new 
records, and screened accordingly.
Eligibility criteria
Papers were assessed for eligibility using six hierarchical 
inclusion criteria. First, papers published in English were 
included, and all others were excluded. Second, publica-
tions in peer-reviewed journals, reports published by NGOs/
HTA bodies, and studies published in discussion papers by 
academic institutions, were included. All other publication 
types, including conference abstracts, were excluded. Third, 
experimental studies in which the stated preferences of par-
ticipants were quantitatively elicited were included. Non-
experimental revealed preference studies, non-quantitative 
studies, and reviews of prior studies, were excluded. Fourth, 
those studies featuring broadly representative samples of the 
UK adult general public were included.3 Studies centred on 
selective samples of the UK population, such as students, 
policy makers and health care professionals were excluded. 
Studies featuring exclusively non-UK respondents, or for 
which it was not possible to isolate the preferences of UK 
respondents, were excluded. Fifth, studies were assessed 
for their ability to provide information on the extent of the 
public’s aversion to inequalities in lifetime health between 
socioeconomic groups. Studies that explicitly asked, or 
2 Note that this keyword supplementation means our search strategy 
captures both the keywords anticipated by the authors, and those used 
in the “pearls” [22]. Also, note that an iterative procedure was used 
to ensure that the search picked up all papers referenced in any of the 
identiied papers. The combination of these two factors means that it 
is unlikely that the choice of pearls will have artiicially narrowed the 
number of studies identiied; although a non-pearl based, non-itera-
tive procedure may have missed some of the studies we identiied.
3 This included samples recruited from limited geographical areas. 
These samples were included, as we were aware that practicality 
means that face-to-face research is commonly conducted in limited 
geographical areas. We did not want to bias our results in favour of 
online, geographically broad samples, and so opted to include these 
geographically limited studies.
How averse are the UK general public to inequalities in health between socioeconomic groups?…
1 3
could be implied as asking, respondents to make eiciency/
equality trade-ofs between individuals, or groups, with dif-
fering lifetime health in a range relevant to socioeconomic 
inequalities in health (life expectancy4 or quality-adjusted 
life expectancy: > 50 and < 90 [1]) were included—irrespec-
tive of whether participants were told they were choosing 
between socioeconomic groups, or between neutrally framed 
groups in a comparable range of lifetime health. Two distinct 
strands of empirical literature were considered to be capable 
of providing this information—(1) stated preference stud-
ies focused on health inequality aversion5 [28–30], and (2) 
stated preference studies focused on eliciting preferences 
regarding prioritising those individuals with a higher Bur-
den of Illness, as deined by their absolute QALY shortfall 
in prospective health attributable to some illness6 [31, 32].
Studies that did not apply a lifetime time-horizon, or that 
could not be utilised to infer aversion to lifetime health, 
were excluded. Stated preference studies that focused on 
severity, as deined by relatively poor quality of life [19], 
and preferences regarding treatment at the end of life [18] 
were excluded for this reason. Studies focused explicitly on 
inequality aversion in the context of gender, or diferences 
in lifestyle, were also excluded. Finally, the choice perspec-
tive employed in each study was evaluated. Those studies 
that asked respondents to make choices in the context of 
public resource allocation decisions that did not afect them 
personally, for example how to allocate inite NHS resources 
between two groups they were not part of, were included. 
Those studies that asked respondents to make choices that 
would impact them, for example their willingness to trade-
away their own wealth, were excluded.
Study selection
Study selection was conducted using a two-step process, 
with titles and abstracts screened irst followed by screening 
of full papers. Eligibility criteria were applied sequentially 
in the order detailed above, with the irst arising reason for 
exclusion recorded. The irst two waves of screening were 
conducted by Simon McNamara. Abigail Steveley then 
independently reviewed a random sample of 20 full papers 
against the eligibility criteria. This independent review iden-
tiied one discrepancy: the decision of whether or not to 
include a study by Petrou et al. [33]. The lead author of 
the study was contacted to clarify whether it used a general 
population sample, which resolved the discrepancy and the 
study was included. The audit identiied no signiicant con-
cerns regarding the screening undertaken.
Results
Search output
In total, 2155 unique records were screened after removing 
duplicates. Of these, 2059 were excluded based upon title 
and abstract alone, and 96 full-text articles were retrieved. 
Of these, 81 were excluded, leaving 15 inal records (Fig. 1) 
[34]. The commonest reason for exclusion of full-text 
articles was the study population. Most of these excluded 
records were based on studies conducted in other countries, 
although a proportion were conducted in selective samples 
of the UK population, such as students or healthcare profes-
sionals. The conduct of the search, and rationale for exclu-
sion of papers, is detailed in a PRISMA low-chart, above 
[34].
Characteristics of included studies
Choice context
Of the 15 studies identiied, 8 provided estimates of aversion 
to inequalities in health between neutrally labelled groups 
[23, 24, 31, 33, 35–38], whilst 7 provided estimates of aver-
sion to inequalities in health between socioeconomic groups 
[6–9, 39–41].
Participants
Forty percent of identiied studies recruited local samples, 
whilst 66.6%7 recruited national samples. The identiied 
studies ranged in size from only 26 participants [40], to 3669 
participants [31]. On average, those studies that provided 
estimates of inequality aversion between neutrally labelled 
groups were substantially larger than those that provided 
evidence of aversion between socioeconomic groups (mean 
n = 1064 vs. n = 154).
4 For the avoidance of doubt, when we refer to “life expectancy” we 
refer to life expectancy from birth, and not remaining life-expectancy 
from a given point in time.
5 This includes studies focused upon the “fair innings” argument, 
and its “extended” version that incorporates quality of life [30]—the 
idea that those individuals who are not expected to experience a ‘nor-
mal’ span of lifetime health should be prioritised over those who are. 
Note that lifetime health is expressed in terms of life expectancy from 
birth in the fair Innings argument, and in terms of quality adjusted life 
expectancy from birth in the extended fair Innings argument.
6 Note that tests of BOI are founded upon shortfall in prospective 
health, rather than lifetime health. However, if we assume the impact 
of BOI on the preferences of the public is linear—as the literature on 
BOI does [31]—then estimates of preferences regarding BOI may be 
used to imply aversion to inequalities in lifetime health. 7 Note that one study featured both a UK level, and local sample [7].
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Mode of administration
The studies used a wide range of administration modes. 
These included individual interviews—both computer 
assisted [35, 36],8 and paper-based [8, 24, 38]—postal 
questionnaires [9, 39], online studies [6, 7, 33, 37], and dis-
cussion groups featuring individual completion of choice 
exercises [7, 23, 40]. Of the discussion groups, one was a 
NICE Citizen’s Council [40].
Methods
The 15 studies applied a variety of diferent methods. Four 
studies utilised a form of beneit trade-of (BTO), based 
upon a design irst developed by Shaw et al. [6–9, 28]. Two 
studies applied discrete choice experiments (DCEs) [36, 37] 
Fig. 1  PRISMA Flow Diagram
8 Note that Lancsar et  al. [36] and Baker et  al. [35] are both part 
of the social value of a QALY project, and that [35] is an overarch-
ing report that contains the results of the discrete choice experiment 
reported in [36], and other parts of the project, including a person 
trade of (PTO) study. Throughout this paper, when we refer to the 
Baker et al. [35] study we are referring to this PTO study.
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featuring multiple attributes, two featured a person trade-
of (PTO) exercise [33, 35], and two featured simple choice 
questions9 [39, 40]. Three studies used a form ranking exer-
cise [33, 38, 41], whilst the remaining two studies featured 
other forms of choice exercise [24, 37].
Whilst a range of different methods were identified, 
these were not spread evenly across choice contexts. Both 
the DCEs [36, 37], and the two PTO [33, 35], studies elic-
ited only aversion to inequalities in lifetime health between 
neutrally labelled groups, whilst all of the four Shaw et al. 
variant BTO studies [28] elicited aversion between socio-
economic groups.
The identiied studies explored a range of diferent meas-
ures of lifetime health, including life-expectancy at birth 
[8, 9, 39, 41], age at death [33, 38], expected number of 
lifetime QALYs—presented as either decomposed proiles10 
[23, 35, 36], or composed values [24], BOI as expressed by 
the QALY [31, 37]—and the number of “years of life in full 
health over the average person’s lifetime” [6, 7]. In those 
studies that elicited aversion to health inequality between 
socioeconomic groups, the labels given to the groups 
included: “the richest” and “the poorest” ifth of society [6, 
7]; having a “wealthy background” or a “poor background” 
[39]; and social (occupational) “Class I” vs “Class V”11 [8, 
9, 41] (Tables 1, 2).
Findings of identiied studies
Of the 15 identiied studies, 8 provide evidence of health 
inequality aversion [6–9, 24, 33, 38], 2 provide evidence 
of no aversion [36, 39], and 5 provide mixed evidence [23, 
31, 35, 37, 40]; see Table 3 above. Seven studies explored 
Table 1  Identiied studies—study characteristics
BTO beneit trade-of, PTO person trade-of, DCE discrete choice experiment, CAPI computer-assisted personal interview, LE life expectancy at 
birth, YFH years of life in full health over the average person’s lifetime, BOI burden of illness
Authors (date) Sample size Sample population Administration method Method Focus of relevant questions 
within study
Ali et al. (2017) [7] 135 York + UK Group with individual 
response + online
BTO Aversion to inequalities in 
YFH
Anand and Wailoo (2000) 
[39]
144 Leicester Postal Simple choice Relevance of cause of inequal-
ity
Baker et al. (2010) [35] 587 England CAPI PTO Social value of the QALY
Dolan and Tsuchiya (2005) 
[23]
100 Sheield Group with individual 
response
Ranking Relevance of past/future health
Dolan and Tsuchiya (2011) 
[8]
130 York Interview BTO Aversion to inequalities in LE
Edlin et al. (2012) [24] 559 England + Wales Interview Other choice Relevance of cause of inequal-
ity
Lancsar et al. (2011) [36] 587 England CAPI DCE Social value of the QALY
NICE (2006) [40] 26 England + Wales Group with individual 
response + Citizens Council
Simple choice Prioritising the socially disad-
vantaged
Petrou et al. (2013) [33] 2500 UK Online PTO + ranking Fair innings
Rowen et al. (2016) [37] 371 UK Interview + online Other choice BOI
Rowen et al. (2016) [31] 3669 UK Online DCE BOI
Robson et al. (2017) [6] 244 England Online BTO Aversion to inequalities in 
YFH
Tsuchiya et al. (2003) [38] 140 York Interview Ranking Fair innings
Tsuchiya and Dolan (2007) 
[9]
271 UK Postal BTO Aversion to inequalities in LE
Tsuchiya and Dolan (2009) 
[41]
128 Sheield Group with individual 
response
Ranking Aversion to inequalities in LE
10 Decomposed = A health proile expressed in terms of length 
of life, and quality of life, not expressed as a QALY value. Com-
posed = A health proile expressed in terms of QALYs.
11 Class I = professional occupation, Class V = unskilled.
9 When we refer to “simple choice questions” we mean questions 
did not present concrete outcome scenarios, and were more generally 
about prioritisation. In contrast, the “other forms” of exercise were 
more traditional choice experiments featuring outcomes, but that 
were not BTO/PTO studies.
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Table 2  Identiied studies—context
BOI burden of illness, LT lifetime, YFH years of life in full health over the average person’s lifetime, DC decomposed (QALY proile presented in 
terms of LE, and QoL, but not as a uniied igure), C composed (QALY igure presented)
a [24] involves choices between diferent proiles, not changes in existing proiles, so this is technically not a “tested change”
b Note that [8] also tested aversion between the “healthiest” and “unhealthiest” quintiles of society, these labels are ambiguous and may be inter-
preted as relecting the lifestyle of these groups, their lifestyle and their outcomes, or their outcomes alone. As a result, they were excluded
c Note that both Rowen et al. papers take a forward looking, rather than lifetime perspective—these studies are included under the assumption 
that BOI has a linear impact upon the preferences of the public (see “Eligibility criteria” for further detail)
Authors (date) Tested inequality Range of relevant inequality Tested change
Ali et al. (2017) [7] YFH YFH: 62–74 YFH
Anand and Wailoo (2000) [39] LE LE: 70–84 Priority
Baker et al. (2010) [35] LT QALYs (DC) LT QALYs: < 76 LT QALYs (DC)
Dolan and Tsuchiya (2005) [23] LT QALYs (DC) LT QALYs: < 66 LT QALYs (DC)
Dolan and Tsuchiya (2011)b [8] LE LE: 73–78 LE
Edlin et al. (2012) [24] LT QALYs (C + DC) LT QALYs: 52–76 LT QALYs (C + DC)a
Lancsar et al. (2011) [36] LT QALYs (DC) LT QALYs: 60–80 LT QALYs (DC)
NICE (2006) [40] General health – Priority
Petrou et al. (2013) [33] Age at death Age at death: 60–90 Extra years at full health
Rowen et al. (2016)c [37] BOI QALYs (DC) Absolute QALY burden framed QALYs (DC)
Rowen et al. (2016)c [31] BOI QALYs (DC) Absolute QALY burden framed QALYs (DC)
Robson et al. (2017) [6] YFH YFH: 62–74 YFH
Tsuchiya et al. (2003) [38] Age at death Age: 55–70 Age at death
Tsuchiya and Dolan (2007) [9] LE LE: 73 vs 78 LE
Tsuchiya and Dolan (2009) [41] LE LE: 73 vs 78 LE
Table 3  Identiied studies—summary of results
a Atkinson inequality aversion parameters are sometimes presented as “r” values, and sometimes presented as “ɛ” values. ɛ = r + 1
b Estimates derived based upon baseline inequality tested in [7] and [8]; 62 YFH vs 74 YFH. Atkinson inequality aversion parameters applied 
where possible—see [8]
Authors (date) Choice context Evidence of aversion to 
inequalities in lifetime 
health?
Atkinson (ɛ) 
 parametera [42]
Weight placed on a marginal 
gain to group with lower lifetime 
 healthe
Ali et al. (2017) [7] Socioeconomic groups Yes 10.87 or greater 6.8–∞
Anand and Wailoo (2000) [39] Socioeconomic groups No 1 (implied) 1
Baker et al. (2010) [35] Neutrally framed groups Mixed – –
Dolan and Tsuchiya (2005) [23] Neutrally framed groups Mixed – –
Dolan and Tsuchiya (2011) [8] Socioeconomic groups Yes 28.9 166.22
Edlin et al. (2012) [24] Neutrally framed groups Yes 5.76–7.63 2.77–3.86
Lancsar et al. (2011) [36] Neutrally framed groups No 1 (implied) 1
NICE (2006) [40] Socioeconomic groups Mixed – –
Petrou et al. (2013) [33] Neutrally framed groups Yes > 1 (implied) > 1
Rowen et al. (2016) [37] Neutrally framed groups Mixed – –
Rowen et al. (2016) [31] Neutrally framed groups Mixed – –
Robson et al. (2017) [6] Socioeconomic groups Yes 10.95 6.95
Tsuchiya et al. (2003) [38] Neutrally framed groups Yes > 1 (implied) > 1 (implied)
Tsuchiya and Dolan (2007) [9] Socioeconomic groups Yes > 1 (implied) > 1 (implied)
Tsuchiya and Dolan (2009) [41] Socioeconomic groups Yes > 1 (implied) > 1 (implied)
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aversion between socioeconomic groups, and eight explored 
aversion between neutrally framed groups.
Aversion to inequalities in health between socioeconomic 
groups
The seven studies that explored aversion between socio-
economic groups provide general, although not universal, 
evidence of aversion to inequalities in lifetime health across 
socioeconomic groups. Five provide support for inequal-
ity aversion [6–9, 41], one study provides mixed evidence 
[40], and one was opposed [39]. In those studies that provide 
evidence of aversion between socioeconomic groups, the 
strength of this preference was high. For example, Dolan 
and Tsuchiya [8] ind that participants valued a marginal 
life-expectancy gain provided to an individual with a social 
class V (unskilled) occupation and a life-expectancy of 73, 
between 6.8 and 9.94 times that of a marginal gain provided 
to an individual with a social class I (professional) occu-
pation with a life-expectancy at birth of 78. Ali et al. [7] 
estimate relative weights of 6.8 to ∞12 on marginal gains, 
in response to questions asking respondents to allocate 
incremental gains in “years in full health over the aver-
age person’s life” (YFH), to a poor individual with a YFH 
of 62 years, compared to a rich individual with a YFH of 
74 years. For the same comparison, Robson et al. [6] ind 
relative weights of 6.20–6.95.13 In contrast, studies where 
aversion between socioeconomic groups was elicited using 
alternative methods found more mixed results. Anand and 
Wailoo [39] ind only 8% of respondents felt that a poor indi-
vidual, who has a life-expectancy of 70 years, should receive 
priority for the treatment of a disease over a rich individual, 
who has a life-expectancy of 85 years. The overwhelming 
majority (92%) believed the two should be treated equally.
One study—a NICE Citizens Council report—pro-
vided mixed evidence of aversion between socioeconomic 
groups [40]. In this study, a minority (40%) of respondents 
agreed that NICE should “issue guidance that concentrates 
resources on improving the health of the whole population 
… even if there is a risk of widening the gap between socio-
economic groups”, whilst a majority (60%) were in favour 
of focusing resources on “the most disadvantaged members 
of our society” (p. 15). However, in the same study, 83% of 
participants agreed with the, seemingly contradictory, state-
ment that “NICE should issue guidance that concentrates 
resources on where it will have the greatest impact on the 
whole population” (p. 23), and only 50% agreed with the 
statement “It is the responsibility of the NHS to attempt to 
narrow the gap between the least and most disadvantaged in 
our society in terms of public health” (p. 24).
Aversion to inequalities in health between neutrally 
labelled groups
Eight studies explored aversion to inequalities in lifetime 
health between neutrally labelled groups, in a range of life-
time health comparable to those tested in socioeconomic 
group framed studies (a quality-adjusted life expectancy or 
life expectancy > 50 and < 90 [1]) [23, 24, 31, 33, 35–38]. 
Three of the eight studies provided support for inequality 
aversion [24, 31, 33, 38], albeit at lower levels than identi-
ied in those studies focused on aversion between socioeco-
nomic groups.
Edlin et al. [24] provide the highest estimate of aversion 
to inequalities in health between neutrally labelled groups. 
In this study, the authors tested aversion to two inequali-
ties. In the irst of these, “study state A” (68 QALYs vs 54 
QALYs) the authors found respondents granted a weight of 
3.1 to an incremental health gain to the worse of group. In 
the second, “study state B” (76 QALYs vs 52 QALYs) the 
authors found a weight of 3.5.14 In contrast, Petrou et al. [33] 
estimate a weight of only 1.37,15 on a 5-year life extension 
at perfect health, provided to someone who would otherwise 
die at age 60 years, compared to someone who would other-
wise die at age 80 years. This inding is consistent with that 
of Tsuchiya et al. [38], who found the public were willing to 
prioritise granting a 5-year survival beneit to a 55-year old 
who will otherwise die immediately, over an equivalent gain 
to a 70-year old, albeit without estimating a precise weight 
on the strength of that preference.
Four of the eight studies provided mixed evidence of 
aversion to inequalities in health between neutrally labelled 
groups. Two of these [31, 37], were focused on quantify-
ing public preferences towards granting priority to those 
individuals who have a higher burden of illness (BOI), as 
expressed by their QALY shortfall, over those with lower 
BOI. In the smallest of these two studies [37], the authors 
asked four questions relevant to this topic.16 Three of these 
14 If the Atkinson inequality aversion parameters (ɛ) estimated by 
Edlin are applied to the inequality tested in [6] and [7], this results in 
estimated weights on marginal gains to the group with lower health 
of 3.86 and 2.77 for A [(74/62)^(6.63 + 1)] and B, respectively, 
[(74/62)^(4.76 + 1)].
15 See Table 5 in Petrou et al. [33]: 0.78/0.57 = 1.37.
16 PQ2, Q1, Q2 and Q3.
12 In these cases, the median respondent violated monotonicity and 
preferred not to grant an incremental health beneit to the better of 
group, even when it came at no opportunity cost to the worse of group.
13 Note that the weights presented for [6] and [7] are not directly com-
parable to those for [8], as [8] used a diferent baseline inequality than 
was tested in [6] and [7]. If the Atkinson inequality aversion parameter 
from [8] is applied to the inequality tested in [6] and [7], this produces 
an implied weight of 166.22 on a marginal gain to a poorer individ-
ual compared to a richer individual [(74/62)^(27.9 + 1)]—see [8] for 
details of how these weights are derived.
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questions provided no support for granting preference to 
those who had a higher BOI, whilst one provided modest 
evidence (59% support) of a preference towards prioritising 
the worse of. In the largest study [31], the same research 
team found evidence of a preference towards treating those 
with higher BOI, over those with lower BOI—implying an 
aversion to inequalities in lifetime health. However, when 
they then deconstructed the impact of BOI into that attrib-
utable to loss of life-expectancy, and loss of health-related 
quality of life, the authors found respondents preferred to 
prioritise those whose BOI was attributable to loss of length 
of life, and made the opposite choices about those who BOI 
was due to losses of health-related quality of life17—a ind-
ing consistent with the fair innings hypothesis, but not the 
extended fair innings hypothesis [30]. This inding is similar 
to that observed by Dolan and Tsuchiya [23], who found 
preferences consistent with aversion to diferences in life-
expectancy, but not quality-adjusted life-expectancy. In both 
of the questions that Dolan and Tsuchiya tested, participants 
ranked the opportunity to provide a health beneit to the 
individual with the lowest lifetime QALYs second to last 
out of the six options tested. This outcome appears to have 
primarily been driven by the fact that respondents were not 
as averse to diferences in past-quality of life as would be 
suggested by the QALY model, and placed a much higher 
emphasis on length of life, than lifetime quality of life.
Baker et al. [35] also ind mixed evidence on inequality 
aversion. In their PTO study, the authors evaluated respond-
ents’ preferences towards granting an incremental health 
gain to individuals who are expected to die at difering 
ages. This gain took the form of a 20% gain in health-related 
quality of life for their last 20 years of life (4 QALYs). In 
response to these questions, the authors found respondents 
preferred to give the incremental beneit to individuals who 
are due to die at age 60 years, rather than those who are due 
to die at age 80 years—with an estimated relative weight 
of 1.5518 on the gain provided to those with lower lifetime 
health. However, in the same study, the authors conducted a 
series of “proile tests” in which the lifetime health of certain 
proiles was varied to test the extended fair-innings hypoth-
esis (e.g. by changing past quality of life, or by granting the 
proiles additional length of life after the tested quality of life 
gain). In these proile tests, the authors ind mixed results, 
with, if anything, “a tendency to favour those with higher 
lifetime health” (p. 45).
The sole study to provide evidence of no aversion to ine-
qualities in health between neutrally labelled groups was that 
by Lancsar et al. [36]. In this DCE study, the authors ind 
that the public place extremely low weights on the lifetime 
health of individuals in comparison to the magnitude of the 
health gain ofered, and that these weights are marginally 
counter to the idea of aversion to inequalities in lifetime 
health. For example, the authors ind the public place an 
incremental weight of 0.94 on an incremental health gain to 
someone with an age of death of 60, compared to someone 
with an age of death of 80.
Discussion
This review set out to do three things. First, to identify esti-
mates of the strength of the UK public’s aversion to ine-
qualities in lifetime health between socioeconomic groups. 
Second, to explore whether the strength of this aversion dif-
fers depending upon the type of health under consideration. 
Third, to explore whether or not aversion difers depend-
ing upon whether participants were told that the inequality 
existed between socioeconomic groups, or neutrally framed 
groups. We identiied 15 studies relevant to these aims.
The identiied studies provide general, although not uni-
versal, support for the idea that the UK public are averse 
to inequalities in life expectancy (at birth) between socio-
economic groups. Similarly, the studies identiied provide 
evidence that the public are averse to inequalities in life-
expectancy (at birth) between neutrally framed groups in 
a comparable range of lifetime health. Eleven of the 15 
studies identiied provide evidence in support of aversion to 
inequalities in total life expectancy [6–9, 23, 24, 31, 33, 35, 
38, 41], two provide evidence in opposition [36, 39], and two 
are inconclusive [37, 40]. However, the strength of aversion 
difered substantially between studies, with higher levels of 
aversion elicited for inequalities presented as being between 
socioeconomic groups than between neutrally framed 
groups. For example, Petrou et al. [33] and Baker et al. [35] 
estimate relative weights of only 1.37 and 1.55, respectively, 
on an incremental health gain provided to someone who will 
die at 60, compared to someone who will die at 80. In con-
trast, Dolan and Tsuchiya [8] estimate weights of 6.8–9.95 
for a marginal health gain provided to an individual of lower 
socioeconomic status with a life-expectancy of 73 compared 
to an individual of higher socioeconomic status with a life-
expectancy of 78. Similarly, it is notable that the Atkinson 
inequality aversion parameters estimated by Edlin et al. [24] 
in a neutral context are substantially lower than those esti-
mated by Robson et al. [6], Ali et al. [7], and Dolan and 
Tsuchiya [8] in a socioeconomic context; see Table 3.
A small number of the identiied studies suggest that 
the public may be more averse to an inequality of a given 
QALY magnitude if that inequality is due to diferences in 
life-expectancy, rather than quality of life. Both Rowen et al. 
17 Note that the questions themselves featured both form of BOI 
simultaneously, and that this efect is a product of the way these two 
were decomposed in the analysis undertaken.
18 See Table 20 in [35]: 0.814/0.527 = 1.55.
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[31] and Dolan and Tsuchiya [23] ind that, whilst the pub-
lic are averse to inequalities in quality-adjusted life expec-
tancy (QALE) attributable to diferences in life-expectancy, 
they are not averse [31], or as averse [23], to inequalities in 
QALE attributable to diferences in quality of life. Similarly, 
in their proile tests, Baker et al. [35] ind that the public 
prefer to prioritise those with better, rather than worse, past 
quality of life. This evidence suggests that public preferences 
regarding inequalities in health may be consistent with the 
“fair innings” argument based on duration of life, but may 
not be consistent with the “extended fair innings” argument 
that adjusts for quality of life [30]. None of the studies iden-
tiied explored the possibility that health inequality aversion 
might depend upon the speciic type of health gain under 
consideration (e.g., comparing aversion in the context of 
pain relief and life extension).
This review has three primary limitations. First, our 
inclusion of studies focused on BOI under the assumption 
that the impact of BOI on preferences is linear, which is an 
assumption that may or may not hold [31]. Sensitivity analy-
sis indicates that the exclusion of the two BOI studies identi-
ied would not have an impact upon our conclusions regard-
ing aversion to life-expectancy at birth. However, one of the 
three studies that suggests aversion to inequalities in lifetime 
health attributable to diferences in quality of life may be 
lower than to those attributable to diferences in length of 
life was a BOI-based study [31]. As a result, the strength of 
this conclusion would be weakened by excluding these stud-
ies. Second, our search was designed to inform distribution-
ally sensitive economic evaluations conducted in the UK, 
and so was restricted to evidence on the views of people in 
the UK. As a consequence, the results themselves may be of 
limited generalisability to other countries. Third, the studies 
identiied are methodologically heterogeneous, and report 
estimates of aversion in diferent ways. This makes it chal-
lenging to compare across studies and, with the exception of 
the four studies for which we calculated Atkinson inequality 
aversion parameters, it prevents any attempt at formal syn-
thesis. The primary strength of this paper is the fact that it is 
the irst systematic review of this kind; notably, we identiied 
more studies than found in a recent unsystematic review of 
health inequality aversion [21].
Four key issues
Our indings raise four issues. First, if the public are averse 
to inequalities in health, does it make sense to continue to 
conduct, and use, distributionally naïve economic evalua-
tions? [43]. Whilst this review demonstrates that it is chal-
lenging to quantify precisely how averse the public are to 
inequalities in health, the evidence available does suggest 
they are averse. The distribution of health gains appears to 
matter to the UK public, and ignoring this preference by 
continuing to conduct distributionally naïve economic evalu-
ation is a choice that runs counter to this preference. Sec-
ond, if we want to introduce consideration of inequalities 
into economic evaluation, what level, or levels, of aversion 
should be implemented in practice?19 This is a critical ques-
tion, because the prioritisation of equality has a human cost 
[30, 44]. If we choose to prioritise equality, we accept there 
will be more sufering, and loss of life, than might other-
wise be present in our society. Conversely, if we choose not 
to prioritize equality, we choose to accept that the social 
burden of ill health will be disproportionately placed on the 
poor. The level of inequality aversion incorporated in an 
economic evaluation would quantify the acceptable human 
cost of a given improvement in equality, and so it is critical 
to deine it in a considered way. This review found wide vari-
ation in estimates of public preferences regarding inequali-
ties across studies, which highlights the challenge of select-
ing a single estimate of aversion to implement. Given this 
variation, those conducting economic evaluations would be 
wise to undertake sensitivity analyses surrounding the rela-
tive weight they give to the distribution of health gains and 
average population health gains. If distributionally sensitive 
economic evaluation is to become more widespread in the 
UK, it would be valuable for a body like NICE or Public 
Health England to deine a reference level of health inequal-
ity aversion (perhaps using a Citizen’s Council comparable 
to [40]), so that those conducting these analyses can present 
their work in a comparable and consistent manner. Again, 
note that if these bodies do not comment on this issue, this 
equates to an endorsement of a status quo in which the reduc-
tion of inequalities in health carries no weight in economic 
evaluation. Third, if aversion to socioeconomic inequalities 
in health is higher than aversion to neutrally framed inequali-
ties of equivalent magnitude, which (if either) strength of 
aversion is the appropriate one to relect in distributionally 
sensitive economic evaluation? Should estimates of aversion 
from neutrally framed studies be used because this removes 
the inluence of non-health factors upon respondents’ prefer-
ences? Or should estimates of aversion from socioeconomi-
cally framed studies be used because this relects the fact 
that inequalities in health between socioeconomic groups are 
systematic, as opposed to being random variation within the 
population, and so may be considered inequitable? Fourth, is 
health inequality aversion consistent with the QALY model, 
or does the type of health matter to the public? If aversion 
does difer depending upon whether the public are asked 
about life-expectancy, pain relief, or any other form of health 
gain: how should this be accounted for in distributionally 
19 Note that this point applies equally to the development of indices 
of population health that account for aversion to inequalities in health 
[48, 49].
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sensitive economic evaluation? Can QALY-based distribu-
tional cost-efectiveness analysis represent the views of the 
public?
In conclusion, this review suggests that the UK public 
are averse to inequalities in life expectancy between socio-
economic groups, albeit with wide variation in the strength 
of this preference between studies. We ind evidence of 
aversion between neutrally framed groups; however, the 
UK public appears to be more averse to inequalities in 
health between socioeconomic groups. We ind limited evi-
dence that the composition of an inequality may impact the 
strength of aversion, and in particular, that the public may 
be less averse to an inequality of a given QALY magnitude 
if that inequality is due to diferences in quality of life, rather 
than life-expectancy.
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